Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00802113 · ClinicalTrials.gov registry record · Phase 1
Autologous and Allogeneic Transplant for Relapsed Lymphoma
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00802113 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 30 participants.
The verdict
NCT00802113, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The sequential combination of myeloablative therapy and autologous stem cell transplantation (APBSCT) followed by a reduced intensity allogeneic stem cell transplant (Allo SCT) and post SCT adoptive cellular immunotherapy will be well tolerated in patients with refractory or recurrent non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Anti-Thymocyte Globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2003-06 |
| Est. Completion | 2014-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00802113
The ClinicalTrials.gov registry entry for NCT00802113 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fludarabine is the first listed.
NCT00802113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00802113 about?
NCT00802113 is a clinical study titled "Autologous and Allogeneic Transplant for Relapsed Lymphoma". The sequential combination of myeloablative therapy and autologous stem cell transplantation (APBSCT) followed by a reduced intensity allogeneic stem cell transplant (Allo SCT) and post SCT adoptive cellular immunotherapy will be well tolerated in patients with refractory or recurrent non-Hodgkin's ...
What is the current status of trial NCT00802113?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2003-06. Estimated completion is 2014-10-22.
What interventions are being tested in trial NCT00802113?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Anti-Thymocyte Globulin (DRUG).
Who is sponsoring clinical trial NCT00802113?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.